ELGAN Pharma

Company Overview

Snapshot

Founded in May 2018 by Miki Olshansky and Stav Zeldis, ELGAN Pharma operates with 11–50 employees. The company has raised $7.5M across three funding rounds from two investors. In June 2025, ELGAN Pharma and Chiesi Group announced the dosing of the first participating infants in a Phase 3 clinical study for ELGN-2112, a treatment for intestinal malabsorption in preterm infants.

Business overview

ELGAN Pharma is a clinical-stage biotechnology company focused on neonatology, developing safe and tailored therapies for medical problems and developmental difficulties common in very premature babies. The company's core products, ELGN-GI and ELGN-EYE, address high unmet medical needs in preterm infants. ELGN-GI aims to promote faster intestinal maturation, reducing dependence on parenteral nutrition, while ELGN-EYE is a local drug designed to prevent vision impairment due to retinopathy of prematurity (ROP). ELGAN Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare market with a focus on babies, patients, and providers.

Strategic signal

In June 2025, ELGAN Pharma, in collaboration with Chiesi Group, initiated a Phase 3 clinical study for ELGN-2112, targeting intestinal malabsorption in preterm infants. This development signals significant progress in the company's clinical pipeline and validates its strategic partnerships, indicating a strong move towards commercialization and addressing critical neonatal health challenges.

Company Intelligence Q&A

What is ELGAN Pharma's primary focus?

ELGAN Pharma is a clinical-stage biotechnology company specializing in neonatology, developing tailored therapies for medical issues and developmental challenges in very premature infants.

What are ELGAN Pharma's leading clinical programs?

ELGAN Pharma has two leading clinical programs: ELGN-GI, which promotes intestinal maturation in infants, and ELGN-EYE, a local drug aimed at preventing vision impairment from retinopathy of prematurity (ROP).

When did ELGAN Pharma announce positive results for its ELGN-GI Phase III study?

In March 2022, ELGAN Pharma announced positive results from its Phase III study of ELGN-GI in preterm infants for the treatment of intestinal malabsorption.

What was a significant development for ELGAN Pharma in June 2025?

In June 2025, ELGAN Pharma and Chiesi Group announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical study of ELGN-2112 for the treatment of intestinal malabsorption in preterm infants.